Palisade Bio, Inc. · NASDAQ:PALI
Palisade Bio — Investor Presentation (November 2023)
26 slides from Palisade Bio's investor presentation, Nov 7, 2023
Slide 1: Corporate Presentation November 2023
palisadebio.com NASDAQ CM: PALI =~, Corporate Presentation é November 2023
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitatio | statements regarding our research and pre-clinical and clinical development plans, expected near and long
Slide 3: Investment Highlights
Investment Highlights Developing novel therapeutics for serious chronic gastrointestinal diseases, with a targeted approach that transforms the treatment landscape KEY HIGHLIGHTS Recent transaction jumpstarts into high-value IBD market Clinically validated PDE4 target utilized by multiple Big Pharma
Slide 4: Our Oral IBD Development Pipeline
Our Oral IBD Development Pipeline Oral Prodrug Therapies that Act Locally at Site of Disease IND/CTA- Program Discovery Enabling Phase 1 Phase 2 Phase 3 a Ongoing IND/CTA-enabling tox studies PALI-2108 Ulcerative C: Rapidly advancing towards IND/CTA filing in 2024 Lead optimization complete Fibro St
Slide 5: Strategic Shift in Prioritization to Newly Licensed Assets
Strategic Shift in Prioritization to Newly Licensed Assets for Treatment of Inflammatory Bowel Diseases We entered into an exclusive worldwide licensing agreement to develop and commercialize proprietary oral prodrug therapies that act locally targeting multi-billion-dollar IBD market Company Secure
Slide 6: Inflammatory Bowel Diseases (IBD)
Inflammatory Bowel Diseases (IBD) Chronic Condition Characterized by Persistent Inflammation in the Digestive Tract Diagnosed in Early Adulthood with Alternating Periods of Activity and Remission ; Symptoms COLITIS i Diarrhea Abdominal pain Fatigue Cramping Blood in your stool Reduced appetite Fibro
Slide 7: IBD is a Large and Growing Market
IBD is a Large and Growing Market Erpectedorcron CURRENT, IBD MARKET, ~ to $20B by 2031' Ree ainecpeutceDemonctatng Ulcerative Colitis Crohn's Disease Safety and Efficacy are Likely to eaiNatiset Stare 1.95 Million 1.63 Million Palisade Bio Has the Only wases Cage PDE4 Under Development pee and CD $
Slide 8: Ulcerative Colitis and Crohn's Disease patient journey
ULCERATIVE COLITIS Ne Of patients have moderate-to-severely Th e | B D active disease 70% Of patients with active disease will M4 have active disease the next year Patient Journey elt ee active disease the next year Of patients with long-lasting UC and Patients and clinicians search out the most = e
Slide 9: Current Standard-of-Care Therapies Have Limited Effectiveness
Current Standard-of-Care Therapies Have Limited Effectiveness No Standard Regimen for Managing All IBD Patients The Approach to Treatment Needs to Be Tailored for the Individual CURRENT FACTORS THAT DETERMINE TREATMENT APPROACH TREATMENT APPROACH 5-ASA is generally first line for ulcerative colitis
Slide 10: PALI-2108 Targeting Ulcerative Colitis
eee id “ ae + PALI-2108 ) Targeting Ulcerative Colitis ' j —— a Ss
Slide 11: Ulcerative Colitis Competitive Landscape
Ulcerative Colitis Competitive Landscape Most Effective Therapies Have Black Box Warning, New Therapies Are Not as Effective Drug @ Remicade RINVOG oS Skyrizi © ZEPOSIA XELJANZ {tofacitini) Company abbvie Bristol Myers Squibb Placebo-Adjusted Clinical Remission 24% (ACT) 21% (U-ACHIEVE) 16.9% (GEMIN
Slide 12: Approach to Ulcerative Colitis
proach to Ulcerative Colitis A Candidate ocally at Site of Disease KEY DIFFERENTIATION v Oral Dosing v Locally Active v Limited Systemic Activity (improved safety) yv Superior Cytokine Blocking Profile v Potential of Breakthrough Clinical Efficacy vy Potential for Precision Medicine Approach
Slide 13: PALI-2108: Mechanism of Action
13 - . ORAL DELIVERY PALI-2108: Mechanism of Action © : * a - 5 Bacterial Ny ; | enzyme “839 =f | —4 9 f x PALI-0008 || SUPERIOR TNF-«. ‘PDES error PRODRUG PDEA INHIBITORNIA| BLOCKING PROFILE _ o% * e 4 Tell » Se. : ¥. as Monocyte « ~ : a 2 : & LIMITED SYSTEMIC. e | Neutrophil ee
Slide 14: PALI-2108 Data Highlights
14 PALI-2108 Data Highlights DSS Mouse Proof of Efficacy Study v Exclusively selective for PDE4 limiting the potential for off-target effects y¥ Isoenzyme inhibition profile comparable to marketed anti-inflammatory and anti-fibrotic PDE4 inhibitor ¥ 20 times more potent as a TNFa inhibitor than apre
Slide 15: PDE4 is an Established Dual Acting Anti-Inflammatory and Anti-Fibrotic Target
PDE4 is an Established Dual Acting (Pleiotropic) Anti-Inflammatory and Anti-Fibrotic Target & COPD (Roflumilast; AstraZeneca): Anti-fibrotic indications AstraZeneca such as chronic obstructive pulmonary disease Psoriasis and Psoriatic Arthritis (Apremilast; Amgen): Anti= AMGEN inflammatory indicatio
Slide 16: Demonstrated High Potential for Locally Acting PDE4
Demonstrated High Potential for Locally Acting PDE4 Two Placebo-Controlled Randomized Trials Have Been Conducted Mild-to-Moderate Moderate-to-Severely Active UC" Active UC2 Weeks Wook 8 =] g 8 z Z H i Proportion ot tpt Aching Sn ee a Placebo 1.25 mg group 50 m9 group Significant improvement in disea
Slide 17: PALI-2108 Development Plan Through Phase 1a/b
PALI-2108 Development Plan Through Phase 1a/b Q2 Q3 Q4 Qi Q2 Q3 Q4 H1 H2 2023 2023 2023 2024 2024 2024 2024 2025 2025 Ww vy we Ne Nd = é >» = IND/CTA-enabling Studies Regulatory Interactions Phase 1a/b Clinical Study 7
Slide 18: Precision Medicine Approach
8 Precision Medicine Approach Precision Medicine Approach for Selecting Patients Most Likely to Respond to PDE4 Therapy in UC PROTEOMICS Changes at the protein level for immune biomarkers, PDE4 expression and PDE4 associated proteins TRANSCRIPTOMICS RNA sequencing of colon tissue to identify express
Slide 19: PALI-1908 Targeting Fibro Stenotic Crohn's Disease
19 ee aS eX OK ® Sao Seele eee. PALI-1908 Targeting Fibro Stenotic Crohn’s Disease
Slide 20: PALI-1908 Targeting Fibro Stenotic Crohn's Disease
20 PALI-1908 Targeting Fibro Stenotic Crohn’s Disease Leverages Same PDE4 Active as PALI-2108 but Modified Prodrug Designed to Target the Upper GI and Specifically Terminal lleum Significant unmet need with no FDA approved vy Highly differentiated by it’s dual therapies for Fibro Stenotic Crohn’s Di
Slide 21: Significant IP Portfolio Through 2042
Significant IP Portfolio Through 2042 Composition of Matter Patent Family PCT/CA2021/050725 National Phase Entry of PCT December 2022 National Phase Entry US, Canada, China, Japan, Mexico, Australia, EU (France, Germany, Italy, Spain, UK, etc.), South Korea Composition of Matter Coverage Until 2042+
Slide 22: Program Team
Program Team eo © 8 ® JD Finley, MT Mitch Jones, MD, PhD Joie Bernard, PhD Adarsh Patel, MSc, BSc CEO cMo Translational Medicine, Technical Affairs Med Affairs Christophe Mellon, PhD Jon Daniels, PhD JF Levesque MSc Patrick Colin, B. Pharm, PhD CMC & Medicinal Chemistry Safety & Tox & Reg (Consultan
Slide 23: Financial Snapshot
23 Financial Snapshot Strong Financial Position with Cash to Fund Operations into 2025 $16.4M Cash As of June 30, 2023 ~S5M Market Cap’ 3M Volume:
Slide 24: Big Pharma is active in IBD with large deals
24 $10.8 Billion Prometheus Acquiredby € MERCK Phase 2a UC | Phase 2a CD $6.7 Billion < 4 4 . ARENA Acquired by ©@Phizer Big Pharma is active in IBD Phase 3 UC | Phase 2 CD and spending big dollars for a 5; . ~$1 Billion+ Royalties _ earlier stage programs. Theravance Sac y Blopharmg AX, Collaborati
Slide 25: Investment Summary
ea Investment Summary Developing novel therapeutics for serious chronic gastrointestinal diseases, with a targeted approach that transforms the treatment landscape Oral therapeutics addressing UC and CD in high-value IBD market Growing body of data demonstrating locally acting, locally acting approa
Slide 26: palisadebio.com Investor Relations
palisadebio.com NASDAQ CM: PALI Investor Relations: JTC Team, LLC 833-475-8247 PALI@jtcir.com